Prediction of improved therapeutics for fabry disease patients generated by mutagenesis of the α-galactosidase A active site, dimer interface, and glycosylation region-Reference-Cited by-同舟云学术

Prediction of improved therapeutics for fabry disease patients generated by mutagenesis of the α-galactosidase A active site, dimer interface, and glycosylation region

Published:2020-11 Issue: Volume:175 Page:105710
ISSN:1046-5928
Container-title:Protein Expression and Purification
language:en
Short-container-title:Protein Expression and Purification

Author:

Stokes Erin S.^ORCID,Gilchrist M. Lane,Calhoun David H.

Funder

ShelbyBioTech LLC

University of Medicine and Dentistry Biomedical Research Support

City University of New York

City College of New York

National Institutes of Health

National Center for Research Resources

Publisher

Elsevier BV

Subject

Biotechnology

Reference45 articles.

1. Human alpha-galactosidase A: glycosylation site 3 is essential for enzyme solubility;Ioannou;Biochem. J.,1998

2. A-galactosidase A defiency: fabry disease;Desnick,1995

3. History of lysosomal storage diseases: an overview;Mehta,2006

4. Fabry disease;Schiffmann;Pharmacol. Ther.,2009

5. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy;Desnick;Ann. Intern. Med.,2003

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel double GLA gene mutation of W24R and N419D in a patient with cardiac Fabry disease;Molecular Genetics and Metabolism Reports;2023-09

2. New Insights into the Cooperativity and Dynamics of Dimeric Enzymes;Chemical Reviews;2023-08-10

3. Optimizing human α-galactosidase for treatment of Fabry disease;Scientific Reports;2023-03-23

4. Brilliant glycans and glycosylation: Seq and ye shall find;International Journal of Biological Macromolecules;2021-10